Meeting Recording

Event Title: Qatar German and Medical Devices Third Quarter 2026 Financial Results Conference Call

Date: 15 November 2026, 02:00pm

Duration: 7m 59s

Sabharish Kumar

Assalamu Alaikum everyone and good afternoon to everyone. Thank you all for taking the time to join today's meeting. My name is Sabharish Kumar and I would like to welcome you all to the QGMD Investor Relations Conference Call for the third quarter of 2026.

Before we begin, please be informed that this meeting will be recorded for the documentation purpose. Now, without further delay, I would like to hand over the floor to Mr. Abdullah Karimi. He is our Investor Relations Officer at QGMD, who will be leading today's meeting, thank you everyone, and Mr. Abdullah, over to you. The floor is yours

Abdullah Karimi

Assalamu Alaikum, good afternoon and welcome everyone, My name is Abdullah Investor Relations Officer and I will be moderating today's meeting, and I would like to introduce our speakers today:

• Mr. Abdulaziz Mohammed Saad Al-Tamimi, the Managing Director of QGMD.

And

• Mr. Muhammad Umer, the Accountant at QGMD.

After presentation we will open the session of Q&A, and I would like to hand over the floor to our Managing Director, Mr. Abdulaziz Al-Tamimi, to begin the presentation.

Abdulaziz Al-Tamimi

Good afternoon, everyone. Thank you for attendance to our conference call for the end of quarter three results. First of all, we are pleased to present the company's financial results for the nine-month period ending September 30, 2026. These results reflect a significant improvement in operational and financial performance compared to the same period in 2025. The company achieved sales of QAR 4.55 million, compared to QAR 3.02 million during the same period in 2025, representing an increase of approximately 50.9%. This growth reflects the company's ongoing efforts to enhance its sales activities.

The improvement in profitability is even more pronounced. Earnings before interest, taxes, depreciation, and amortization (EBITDA) and Extraordinary Revenue, reached QAR 2.58 million during the first nine months of 2026, compared to QAR 0.50 million in the same period of 2025. This represents a significant improvement in core operating performance. The company's performance demonstrates the positive impact of measures taken to improve operational efficiency, manage costs, and optimize the use of existing resources and facilities.
Furthermore, the company is allocating a portion of the cash flow generated from this improved operational performance to repay and settle outstanding debts and obligations. This will contribute to easing the financial burden, improving the company's financial position, and enhancing its ability to meet its existing commitments.
The company affirms its commitment to maintaining this positive momentum throughout the remainder of 2026. It will continue to focus on revenue growth, operational efficiency, cost optimization, strengthening internal controls and governance, and expanding its business activities to establish a stronger and more sustainable financial position in the future.
Thank you.

Abdullah Karimi
Thank you, Mr. Umer. The floor is yours, please.

Abdulaziz Al-Tamimi
Yes Mr. Umer will give you the result of our financial September 30th 2026.

Muhammad Umer
Good afternoon.
Let's start with the Balance Sheet as of 30 September 2026.
Total assets at the end of September stood at around QR 131.7 million, compared to QR 134.7 million at year end 2025. The slight decrease is mainly due to normal depreciation on fixed assets.
Looking at our non-current assets, Property, Plant & Equipment remains the largest component at QR 92.2 million. We also have QR 8.2 million in intangible assets and QR 12.4 million in investment property.
Moving to current assets, inventory closed at QR 14.6 million, slightly lower than last year, while receivables increased to QR 4.1 million, reflecting business activity during the period. Cash balance at the end of September was around QR 0.1 million

On the equity side, share capital remained unchanged at QR 115.5 million. However, accumulated losses increased to QR 184.2 million, mainly due to the loss recorded during the period, resulting in a negative equity position of QR 24.8 million
Coming to liabilities, total liabilities stood at QR 156.6 million, with borrowings continuing to be the major component. Long-term borrowings amounted to approximately QR 132.4 million, while current borrowings increased to QR 9.2 million.
Moving to the Profit & Loss statement for the nine-month period ended September 2026.
The revenue increased significantly during the period. Revenue reached QR 4.55 million, compared to QR 3.02 million during the same period last year, which represents an increase of more than 50%.
At the same time, cost of sales remained relatively stable at QR 2.36 million. As a result, gross profit improved substantially from QR 0.68 million last year to QR 2.19 million this year.
Other income also increased slightly to QR 2.22 million, mainly driven by rental income from the company's investment property.
From an expense perspective, general and administrative expenses reduced from QR 5.5 million to QR 5.1 million, which reflects continued cost control measures. Finance costs also reduced significantly compared to last year.
Despite these operational improvements, the company reported a net loss of QR 1.43 million for the period.
To summarize, Q3 2026 showed encouraging operational progress. Revenue grew strongly, gross profit improved significantly, expenses were better controlled, and finance costs reduced
Thank you so much.

Abdullah Karimi

Thank you, Mr. Umer. Now we will open the floor for a Q&A session. So if anyone has any question regarding the financial result, please feel free to ask.
Since there is no any questions, on behalf of Qatari German for Medical Devices Company, I would like to thank all participants for joining us today. Thank you everyone and have a great day.